London, United Kingdom. July 7th, 2025 ConserV Bioscience Limited, 4basebio plc, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) announce that the UK and Canadian governments are providing up to a combined £1.2 million (C$2.2 million) in funding to develop and manufacture a broadly protective influenza vaccine. This project is supported through the Canada-UK 2024-25 collaborative industrial R&D call for proposals on enabling technologies and innovations for biomanufacturing of biologics and advanced therapeutics. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP). Over two years, the new collaboration will employ next generation nucleic acid vaccine and delivery technologies, developed by 4Basebio and Pegasus Biotech, to combine seasonal influenza vaccines with…Read More […]
Read More…